Intra-Cellular Therapies Inc

US

Health Care

74.54 ₽

Current price

Hold
74.54 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    456 / 1328

  • Position in country

    3541 / 14179

  • Return on Assets, %

    -19.3

    -2.7

  • Net income margin, %

    -21.7

    2.8

  • EBITDA margin, %

    -25.8

    10.8

  • Debt to Equity, %

    0

    19.2

  • Intangible assets and goodwill, %

    0

    3.6

  • Revenue CAGR 3Y, %

    173

    8.5

  • Total Equity change 1Y, %

    -9.9

    0

  • Revenue Y, % chg

    85.5

    0.5

  • P/BV

    10.7

    1.5

  • P/S

    13.7

    2.3

  • EV/S

    12.6

    2.4

  • EV/EBITDA

    -40.2

    7.4

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    24.4

    51.3

  • Expected dividend per share

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Royalty Pharma PLC

    00%

  • Zoetis Inc

    00%

  • Intra-Cellular Therapies Inc

    00%

  • Eli Lilly and Co

    00%

  • Bristol-Myers Squibb Co

    00%

  • Johnson & Johnson

    00%

  • Viatris Inc

    00%

  • Merck & Co Inc

    00%

  • Pfizer Inc

    00%

  • Catalent Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    6377.6

  • Ticker

    ITCI.O

  • ISIN

    US46116X1019

  • IPO date

    2014-01-31

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-22

  • Date fact. publication of reports

    2023-12-31

Company Description

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: